Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Liabilities (2016 - 2025)

Historic Total Liabilities for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $7.5 million.

  • China Pharma Holdings' Total Liabilities rose 797.76% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 797.76%. This contributed to the annual value of $7.1 million for FY2024, which is 2079.92% down from last year.
  • Latest data reveals that China Pharma Holdings reported Total Liabilities of $7.5 million as of Q3 2025, which was up 797.76% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Total Liabilities ranged from a high of $16.6 million in Q4 2021 and a low of $6.9 million during Q2 2024
  • For the 5-year period, China Pharma Holdings' Total Liabilities averaged around $10.7 million, with its median value being $11.3 million (2021).
  • In the last 5 years, China Pharma Holdings' Total Liabilities soared by 2683.06% in 2021 and then crashed by 3963.26% in 2024.
  • Over the past 5 years, China Pharma Holdings' Total Liabilities (Quarter) stood at $16.6 million in 2021, then dropped by 18.87% to $13.5 million in 2022, then crashed by 33.2% to $9.0 million in 2023, then dropped by 20.8% to $7.1 million in 2024, then grew by 4.92% to $7.5 million in 2025.
  • Its Total Liabilities stands at $7.5 million for Q3 2025, versus $7.3 million for Q2 2025 and $7.2 million for Q1 2025.